Clinical Trials

Our clinical development program is focused on improving the clinical benefit of late-stage cancer patients utilizing innovative epigenetic approaches targeting histone deacetylases (HDACs) and lysine-specific demethylase 1 (LSD1) either in monotherapy, or in combination with existing therapies.


RESMAIN – Pivotal clinical study of resminostat as maintenance therapy in cutaneous T‑cell lymphoma

Our most advanced program evaluating resminostat in patients with cutaneous T‑cell lymphoma (CTCL), is at the pivotal stage of development in more than 50 centers in 11 European countries.

Press Release

 

Overall survival benefit for resminostat in first-line liver cancer study subgroup

Addition of resminostat to the standard of care sorafenib resulted in prolonged time until disease progression and a substantial benefit in median overall survival in a large subgroup of patients with a normal to high platelet count at study entry (50% of all patients in the study).

For these subgroup patients with higher baseline platelet levels, the risk of death during the study was reduced by approximately 40%, which represents a substantial benefit for patients with advanced HCC who have very few therapeutic alternatives.
Frank Hermann, M.D. | CDO

At median, patients in this subgroup treated with resminostat and sorafenib survived for 13.7 months compared to 5.1 months in patients treated with sorafenib alone.

The Phase II trial evaluated the combination of sorafenib and resminostat versus sorafenib as first-line therapy in 170 patients with liver cancer (hepatocellular carcinoma, HCC) in Japan and Korea.

Press Release

Share this page:

Follow us on: